A Congressional committee is stepping up pressure on three of the largest purveyors of opioids — Purdue Pharma, Mallinckrodt (MNK), and Insys Therapeutics (INSY) — by seeking a raft of documents concerning their controversial marketing and distribution practices.

In letters sent on Thursday to the companies, the House Energy and Commerce Committee asked the drug makers to provide information pertinent to their role in the opioid crisis, such as relationships with doctors, oversight of suspicious orders, funding to outside organizations, training for sales reps, and policies for educational programs, among other things.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • OMG, when are you guy’s going to realize that the people that are ODing are doing it from the fentanyl that is on the streets. The people that have the prescriptions are subject to strict guidelines and they are followed because this medicine is the only kind that helos with the pain and they can lead a halfass normal life. Go after the heroin and fentanyl dealers not the 60 and older USCitizens with limited funds and chronic pain, geezzz

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy